Modulation of Direct Pathway Striatal Projection Neurons by Muscarinic M4-Type Receptors Teresa Hernandez-Flores, Omar Hernandez-Gonz Alez, María B

Total Page:16

File Type:pdf, Size:1020Kb

Modulation of Direct Pathway Striatal Projection Neurons by Muscarinic M4-Type Receptors Teresa Hernandez-Flores,� Omar Hernandez-Gonz� Alez,� María B Neuropharmacology 89 (2015) 232e244 Contents lists available at ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm Modulation of direct pathway striatal projection neurons by muscarinic M4-type receptors Teresa Hernandez-Flores, Omar Hernandez-Gonz alez, María B. Perez-Ramírez, Esther Lara-Gonzalez, Mario A. Arias-García, Mariana Duhne, Azucena Perez-Burgos, * G. Aleph Prieto, Alejandra Figueroa, Elvira Galarraga, Jose Bargas Division de Neurociencias, Instituto de Fisiología Celular, Universidad Nacional Autonoma de Mexico, PO Box 70-253, Mexico City, DF 04510, Mexico article info abstract Article history: Models of basal ganglia (BG) function posit a dynamic balance between two classes of striatal projection Received 7 July 2014 neurons (SPNs): direct pathway neurons (dSPNs) that facilitate movements, and indirect pathway Received in revised form neurons (iSPNs) that repress movement execution. Two main modulatory transmitters regulate the 12 September 2014 output of these neurons: dopamine (DA) and acetylcholine (ACh). dSPNs express D -type DA, M -and Accepted 23 September 2014 1 1 M -type ACh receptors, while iSPNs express D -type DA and M -type ACh receptors. Actions of M -, D -, Available online 5 October 2014 4 2 1 1 1 and D2-receptors have been extensively reported, but we still ignore most actions of muscarinic M4-type receptors. Here, we used whole-cell recordings in acutely dissociated neurons, pharmacological tools Keywords: Acetylcholine such as mamba-toxins, and BAC D1 or 2-eGFP transgenic mice to show that activation of M4-type re- 2þ Striatum ceptors with bath applied muscarine enhances Ca -currents through CaV1-channels in dSPNs and not in Striatal projection neurons iSPNs. This action increases excitability of dSPNs after both direct current injection and synaptically 2þ Excitability driven stimulation. The increases in Ca -current and excitability were blocked specifically by mamba 2þ CaV1Ca -channels toxin-3, suggesting mediation via M4-type receptors. M4-receptor activation also increased network activity of dSPNs but not of iSPNs as seen with calcium-imaging techniques. Moreover, actions of D1-type and M4-type receptors may add to produce a larger enhancement of excitability of dSPNs or, paradox- ically, oppose each other depending on the order of their activation. Possible implications of these findings are discussed. © 2014 Elsevier Ltd. All rights reserved. 1. Introduction express D2-type DA receptors that decrease their excitability in part þ by reducing the same Ca2 -current (Hernandez-L opez et al., 2000; The basal ganglia (BG) are thought to select motor actions, Salgado et al., 2005). Both dSPNs and iSPNs express M1-type ACh participate in cognition and procedural memory (Gerfen and receptors that increase neuronal excitability in part by depressing þ þ Surmeier, 2011). A model of the BG proposes that direct pathway K -currents directly or indirectly and by enhancing persistent Na - striatal projection neurons (dSPNs) facilitate movement whereas currents (Galarraga et al.,1999; Carrillo-Reid et al., 2009b; Goldberg indirect pathway projection neurons (iSPNs) repress movement et al., 2012; Perez-Rosello et al., 2005; Shen et al., 2005, 2007; (Albin et al., 1989; DeLong, 1990; Kravitz et al., 2010). BG are Vilchis et al., 2002). M1-type receptors modulate high voltage þ regulated by two modulatory transmitters whose higher brain activated (HVA) calcium currents involved in activating Ca2 - þ concentrations are in the striatum (Contant et al., 1996; Prensa and dependent K -currents fixing firing patterns and regulating trans- Parent, 2001; Shultz, 2007; Zhou et al., 2002): dopamine (DA) and mitter release (Dolezal and Tucek, 1999; Galarraga et al., 1999; acetylcholine (ACh). dSPNs express D1-type DA receptors that in- Howe and Surmeier, 1995; Perez-Burgos et al., 2008, 2010; Perez- þ crease their excitability in part by enhancing Ca2 -current through Rosello et al., 2005). CaV1-channels (Galarraga et al., 1997; Hernandez-Lopez et al., 1997; The actions of M1-type receptors have been extensively Surmeier et al., 2011; Tritsch and Sabatini, 2012), while iSPNs explored. However, we do not know much about muscarinic M4- type receptors, preferentially expressed in dSPNs (Goldberg et al., 2012; Ince and Ciliax, 1997; Santiago and Potter, 2001; Yan et al., * Corresponding author. Tel.: þ52 55 5622 5670. E-mail address: [email protected] (J. Bargas). 2001). http://dx.doi.org/10.1016/j.neuropharm.2014.09.028 0028-3908/© 2014 Elsevier Ltd. All rights reserved. T. Hernandez-Flores et al. / Neuropharmacology 89 (2015) 232e244 233 Here, we chose to use potent pharmacological tools, mamba- voltage ramps (Hernandez-Gonz alez et al., 2014; Prieto et al., 2009, 2011; Perez- toxins, on isolated neurons obtained from bacterial artificial chro- Burgos et al., 2008, 2010; Perez-Rosello et al., 2005). mosome (BAC) transgenic mice expressing enhanced green fluo- rescent protein (eGFP) associated with dopamine (DA) receptors 2.3. Current clamp recordings In addition, we recorded from brain slices of BAC D or D eGFP transgenic mice. promoters: D1 and D2 receptors (Gerfen and Surmeier, 2011)to 1 2 Slices were submerged in an iced saline solution containing (in mM): 124 NaCl, 2.5 show that activation of M4-type receptors increase the excitability KCl, 1.3 MgCl2, 2 CaCl2, 26 NaHCO3, 1.2 NaH2PO4 and 15 glucose (pH 7.4, 300 mOsm/l, of dSPNs and that the mechanism of action involves the enhance- saturated with 95% O2 and 5% CO2; temperature was maintained around 34 C) and 2þ ment of Ca -currents through CaV1-channels. were left for equilibration in this oxygenated saline at room temperature for 1h. Main experiments were done in dissociated neurons from BAC- Single slices were transferred to a submerged recording chamber and super- e mice to avoid indirect actions. However, complementary experi- fused continuously with oxygenated saline (4 5 ml/min; 25 C). Current-clamp recordings were performed with the patch clamp technique in the whole cell ments in slices supported the conclusion that M4-receptors configuration in SPNs from the dorsal striatum. The slices were visualized using modulate synaptically driven and network activities in dSPNs. infrared differential interference contrast (IR-DIC) microscopy with an upright mi- croscope and a digital camera. Data acquisition used software designed in the 2. Materials and methods LabVIEW environment (National Instruments, Austin TX). Patch pipettes (3e6MU) were filled with internal saline containing (in mM): 115 2.1. Preparation of slices and dissociated cells KH2PO4, 2 MgCl2, 10 HEPES, 1.1 EGTA, 0.2 ATP, 0.2 GTP, and 5% biocytin (pH ¼ 7.2; The protocols followed the National University of Mexico (UNAM) and the Na- 285 mOsm/l). Nominally corticostriatal suprathreshold responses were evoked and tional Institutes of Health guide for the care and use of laboratory animals (NIH recorded by stimulating sensory-motor cortical areas with concentric bipolar elec- Publications No. 8023, revised 1996) including minimizing the number of animals to trodes (50 mm at the tip; FHC, Bowdoinham, ME). The distance between recording achieve statistical significance and the avoidance of animal suffering. Brain slices and stimulating electrodes was about 1 mm. Synaptic responses were evoked by a and acutely dissociated neurons were obtained as described in previous work series of current pulses of increasing intensities until eliciting suprathreshold (Bargas et al., 1994; Perez-Burgos et al., 2008, 2010). BAC D1 or D2-eGFP transgenic male mice (BAC D1-eGFP mice, https://www.mmrrc.org/catalog/sds.php?mmrrc_ id¼297, RRID:IMSR_MMRRC:000297; BAC D2-eGFP mice, https://www.mmrrc.org/ catalog/sds.php?mmrrc_id¼230, RRID:IMSR_MMRRC:000230; postnatal days 60e90) were anesthetized with a mixture of ketamine (85 mg/kg ip) and xylazine (15 mg/kg ip), decapitated, their brains removed and submerged in iced saline so- lution containing (in mM): 126 NaCl, 3 KCl, 26 NaHCO3, 2 CaCl2, 1 MgCl2, 11 glucose, 0.2 thiourea and 0.2 of ascorbic acid (25 C; pH ¼ 7.4 with HCl, 300 ± 5 mOsm/l with glucose; saturated with 95% O2 and 5% CO2). When using the other preparations described below, animals were anesthetized in a similar way. Sagittal brain slices, 300 mm thick, were cut on a vibratome (Pelco 102, Ted Pella. INC) and placed for 1 h at 34 C in the same saline solution. To obtain dissociated cells the dorsal neo- striatum was dissected from the slices and then returned into the saline solution containing 10 mM HEPES plus 1 mg/ml of pronase E type XIV (SigmaeAldrich-RBI, Cat # P5147; St. Louis, MO, USA) at 34 C. After about 20 min of digestion, the slices 2þ were transferred to a low Ca (0.4 mM CaCl2) saline solution to obtain the cells by mechanical dissociation with a graded series of fire-polished Pasteur pipettes. The cell suspension (1 ml) was plated into a Petri dish mounted on the stage of an inverted microscope. Neurons adhered to the bottom of the dish within 10e15 min. The dish contained 1 ml of the whole-cell recording saline (in mM): 0.001 tetro- dotoxin (TTX), 140 NaCl, 3 KCl, 5 BaCl2, 2 MgCl2, 10 HEPES, and 10 glucose (pH ¼ 7.4 with NaOH; 300 ± 5 mOsm/l with glucose). Thereafter, the cells were superfused at 1 ml/min with saline of the same composition at room temperature (around 25 C). eGFP-positive neurons were visualized using a UV lamp (X-Cite; EXFO, Ontario, Canada). 2.2. Voltage clamp recordings of calcium currents Voltage-clamp recordings were performed on eGFPþ SPNs obtained from BAC D1 or D2 mice. Cells had 10e12 mm of main diameter, whole-cell capacitance of 6e7 pF and with short dendritic trunks (Perez-Burgos et al., 2010; Yan and Surmeier, 1996). Patch pipettes of borosilicate glass (WPI, Sarasota, FL, USA) were pulled in a Flaming-Brown puller (Sutter Instrument Corporation, Novato, CA, USA) and fire polished prior to use.
Recommended publications
  • Distinct Muscarinic Acetylcholine Receptor Subtypes Contribute to Stability and Growth, but Not Compensatory Plasticity, of Neuromuscular Synapses
    14942 • The Journal of Neuroscience, November 25, 2009 • 29(47):14942–14955 Development/Plasticity/Repair Distinct Muscarinic Acetylcholine Receptor Subtypes Contribute to Stability and Growth, But Not Compensatory Plasticity, of Neuromuscular Synapses Megan C. Wright,1 Srilatha Potluri,1 Xueyong Wang,2 Eva Dentcheva,1 Dinesh Gautam,3 Alan Tessler,1,4 Ju¨rgen Wess,3 Mark M. Rich,2 and Young-Jin Son1 1Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania 19129, 2Department of Neuroscience, Cell Biology, and Physiology, Wright State University, Dayton, Ohio 45435, 3Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892, and 4Department of Neurology, Department of Veterans Affairs Hospital, Philadelphia, Pennsylvania 19104 Muscarinic acetylcholine receptors (mAChRs) modulate synaptic function, but whether they influence synaptic structure remains un- known. At neuromuscular junctions (NMJs), mAChRs have been implicated in compensatory sprouting of axon terminals in paralyzed or denervated muscles. Here we used pharmacological and genetic inhibition and localization studies of mAChR subtypes at mouse NMJs to demonstrate their roles in synaptic stability and growth but not in compensatory sprouting. M2 mAChRs were present solely in motor neurons,whereasM1 ,M3 ,andM5 mAChRswereassociatedwithSchwanncellsand/ormusclefibers.BlockadeofallfivemAChRsubtypes with atropine evoked pronounced effects,
    [Show full text]
  • Muscarinic Acetylcholine Type 1 Receptor Activity Constrains Neurite Outgrowth by Inhibiting Microtubule Polymerization and Mito
    fnins-12-00402 June 26, 2018 Time: 12:46 # 1 ORIGINAL RESEARCH published: 26 June 2018 doi: 10.3389/fnins.2018.00402 Muscarinic Acetylcholine Type 1 Receptor Activity Constrains Neurite Outgrowth by Inhibiting Microtubule Polymerization and Mitochondrial Trafficking in Adult Sensory Neurons Mohammad G. Sabbir1*, Nigel A. Calcutt2 and Paul Fernyhough1,3 1 Division of Neurodegenerative Disorders, St. Boniface Hospital Research Centre, Winnipeg, MB, Canada, 2 Department of Pathology, University of California, San Diego, San Diego, CA, United States, 3 Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB, Canada The muscarinic acetylcholine type 1 receptor (M1R) is a metabotropic G protein-coupled Edited by: receptor. Knockout of M1R or exposure to selective or specific receptor antagonists Roberto Di Maio, elevates neurite outgrowth in adult sensory neurons and is therapeutic in diverse University of Pittsburgh, United States models of peripheral neuropathy. We tested the hypothesis that endogenous M1R Reviewed by: activation constrained neurite outgrowth via a negative impact on the cytoskeleton Roland Brandt, University of Osnabrück, Germany and subsequent mitochondrial trafficking. We overexpressed M1R in primary cultures Rick Dobrowsky, of adult rat sensory neurons and cell lines and studied the physiological and The University of Kansas, United States molecular consequences related to regulation of cytoskeletal/mitochondrial dynamics *Correspondence: and neurite outgrowth. In adult primary neurons, overexpression of M1R caused Mohammad G. Sabbir disruption of the tubulin, but not actin, cytoskeleton and significantly reduced neurite [email protected] outgrowth. Over-expression of a M1R-DREADD mutant comparatively increased neurite Specialty section: outgrowth suggesting that acetylcholine released from cultured neurons interacts This article was submitted to with M1R to suppress neurite outgrowth.
    [Show full text]
  • WO 2017/177262 Al 19 October 2017 (19.10.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/177262 Al 19 October 2017 (19.10.2017) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/198 (2006.01) A61P 27/02 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 31/375 (2006.01) A61P 27/10 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (21) International Application Number: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, PCT/AU20 17/0503 10 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (22) International Filing Date: NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 10 April 2017 (10.04.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (25) Filing Language: English ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 2016901339 11 April 2016 ( 11.04.2016) AU GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: UNIVERSITY OF CANBERRA [AU/AU]; TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, University Drive, Bruce, Australian Capital Territory 2617 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (AU).
    [Show full text]
  • Muscarinic Toxin 7 Signals Via Ca2+/Calmodulin-Dependent Protein Kinase Kinase Β to Augment Mitochondrial Function and Prevent Neurodegeneration
    Molecular Neurobiology (2020) 57:2521–2538 https://doi.org/10.1007/s12035-020-01900-x Muscarinic Toxin 7 Signals Via Ca2+/Calmodulin-Dependent Protein Kinase Kinase β to Augment Mitochondrial Function and Prevent Neurodegeneration Ali Saleh1 & Mohammad Golam Sabbir1 & Mohamad-Reza Aghanoori1,2 & Darrell R. Smith1 & Subir K. Roy Chowdhury1 & Lori Tessler1 & Jennifer Brown1 & Eva Gedarevich3 & Markos Z. Kassahun3 & Katie Frizzi3 & Nigel A. Calcutt 3 & Paul Fernyhough1,2 Received: 9 January 2020 /Accepted: 9 March 2020 /Published online: 20 March 2020 # The Author(s) 2020 Abstract Mitochondrial dysfunction is implicated in a variety of neurodegenerative diseases of the nervous system. Peroxisome proliferator–activated receptor-γ coactivator-1α (PGC-1α) is a regulator of mitochondrial function in multiple cell types. In sensory neurons, AMP-activated protein kinase (AMPK) augments PGC-1α activity and this pathway is depressed in diabetes leading to mitochondrial dysfunction and neurodegeneration. Antimuscarinic drugs targeting the muscarinic acetylcholine type 1 receptor (M1R) prevent/reverse neurodegeneration by inducing nerve regeneration in rodent models of diabetes and chemotherapy-induced peripheral neuropathy (CIPN). Ca2+/calmodulin-dependent protein kinase kinase β (CaMKKβ)isan upstream regulator of AMPK activity. We hypothesized that antimuscarinic drugs modulate CaMKKβ to enhance activity of AMPK, and PGC-1α, increase mitochondrial function and thus protect from neurodegeneration. We used the specific M1R antagonist muscarinic toxin 7 (MT7) to manipulate muscarinic signaling in the dorsal root ganglia (DRG) neurons of normal rats or rats with streptozotocin-induced diabetes. DRG neurons treated with MT7 (100 nM) or a selective muscarinic antagonist, pirenzepine (1 μM), for 24 h showed increased neurite outgrowth that was blocked by the CaMKK inhibitor STO-609 (1 μM) or short hairpin RNA to CaMKKβ.
    [Show full text]
  • 1: Gastro-Intestinal System
    1 1: GASTRO-INTESTINAL SYSTEM Antacids .......................................................... 1 Stimulant laxatives ...................................46 Compound alginate products .................. 3 Docuate sodium .......................................49 Simeticone ................................................... 4 Lactulose ....................................................50 Antimuscarinics .......................................... 5 Macrogols (polyethylene glycols) ..........51 Glycopyrronium .......................................13 Magnesium salts ........................................53 Hyoscine butylbromide ...........................16 Rectal products for constipation ..........55 Hyoscine hydrobromide .........................19 Products for haemorrhoids .................56 Propantheline ............................................21 Pancreatin ...................................................58 Orphenadrine ...........................................23 Prokinetics ..................................................24 Quick Clinical Guides: H2-receptor antagonists .......................27 Death rattle (noisy rattling breathing) 12 Proton pump inhibitors ........................30 Opioid-induced constipation .................42 Loperamide ................................................35 Bowel management in paraplegia Laxatives ......................................................38 and tetraplegia .....................................44 Ispaghula (Psyllium husk) ........................45 ANTACIDS Indications:
    [Show full text]
  • Venom Week 2012 4Th International Scientific Symposium on All Things Venomous
    17th World Congress of the International Society on Toxinology Animal, Plant and Microbial Toxins & Venom Week 2012 4th International Scientific Symposium on All Things Venomous Honolulu, Hawaii, USA, July 8 – 13, 2012 1 Table of Contents Section Page Introduction 01 Scientific Organizing Committee 02 Local Organizing Committee / Sponsors / Co-Chairs 02 Welcome Messages 04 Governor’s Proclamation 08 Meeting Program 10 Sunday 13 Monday 15 Tuesday 20 Wednesday 26 Thursday 30 Friday 36 Poster Session I 41 Poster Session II 47 Supplemental program material 54 Additional Abstracts (#298 – #344) 61 International Society on Thrombosis & Haemostasis 99 2 Introduction Welcome to the 17th World Congress of the International Society on Toxinology (IST), held jointly with Venom Week 2012, 4th International Scientific Symposium on All Things Venomous, in Honolulu, Hawaii, USA, July 8 – 13, 2012. This is a supplement to the special issue of Toxicon. It contains the abstracts that were submitted too late for inclusion there, as well as a complete program agenda of the meeting, as well as other materials. At the time of this printing, we had 344 scientific abstracts scheduled for presentation and over 300 attendees from all over the planet. The World Congress of IST is held every three years, most recently in Recife, Brazil in March 2009. The IST World Congress is the primary international meeting bringing together scientists and physicians from around the world to discuss the most recent advances in the structure and function of natural toxins occurring in venomous animals, plants, or microorganisms, in medical, public health, and policy approaches to prevent or treat envenomations, and in the development of new toxin-derived drugs.
    [Show full text]
  • Fluticasone Furoate and Vilanterol for the Treatment of Chronic Obstructive Pulmonary Disease
    Expert Review of Respiratory Medicine ISSN: 1747-6348 (Print) 1747-6356 (Online) Journal homepage: http://www.tandfonline.com/loi/ierx20 Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease Gaetano Caramori, Paolo Ruggeri, Paolo Casolari, Kian Fan Chung, Giuseppe Girbino & Ian M. Adcock To cite this article: Gaetano Caramori, Paolo Ruggeri, Paolo Casolari, Kian Fan Chung, Giuseppe Girbino & Ian M. Adcock (2017): Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease, Expert Review of Respiratory Medicine, DOI: 10.1080/17476348.2017.1386564 To link to this article: http://dx.doi.org/10.1080/17476348.2017.1386564 Accepted author version posted online: 28 Sep 2017. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ierx20 Download by: [Imperial College London Library] Date: 29 September 2017, At: 01:13 Publisher: Taylor & Francis Journal: Expert Review of Respiratory Medicine DOI: 10.1080/17476348.2017.1386564 Review Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease Gaetano Caramori1*, Paolo Ruggeri1, Paolo Casolari2, Kian Fan Chung3, Giuseppe Girbino1, Ian M. Adcock3. 1Unità Operativa Complessa di Pneumologia, Dipartimento di Scienze Biomediche, Odontoiatriche e delle Immagini Morfologiche e Funzionali (BIOMORF) Università degli Studi di Messina, Italy. 2Centro Interdipartimentale per lo Studio delle Malattie Infiammatorie delle Vie Aeree e Patologie Fumo-correlate (CEMICEF; formerly Centro di Ricerca su Asma e BPCO), Sezione di Medicina Interna e Cardiorespiratoria, Università di Ferrara, Ferrara, Italy. 3Airways Disease Section, National Heart and Lung Institute, Royal Brompton Hospital Biomedical Research Unit, Imperial College London, UK.
    [Show full text]
  • Oregon Drug Use Review / Pharmacy & Therapeutics Committee
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Oregon Drug Use Review / Pharmacy & Therapeutics Committee Thursday, January 25, 2018 1:00 - 5:00 PM Barbara Roberts Human Services Building 500 Summer St. NE Salem, OR 97301 MEETING AGENDA NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9). I. CALL TO ORDER 1:00 PM A. Roll Call & Introductions R. Citron (OSU) B. Roles and Responsibilities of Committee Members T. Douglass (OHA) C. Conflict of Interest Declaration R. Citron (OSU) D. Election of Chair & Vice Chair R. Citron (OSU) E. Department and Legislative Update T. Douglass (OHA) F. Approval of Agenda and Minutes II. CONSENT AGENDA TOPICS R. Citron (OSU) 1:25 PM A. Noctiva® (desmopressin) Abbreviated Drug Review B. Drugs for Asthma and COPD Literature Scan 1. Public Comment III. DUR NEW BUSINESS 1:30 PM A. Hepatitis C Direct-Acting Antivirals Policy Discussion R. Citron (OSU) 1. Prior Authorization Criteria A. Seaman (OHSU) 2. Treatment of Hepatitis C in People who Inject Drugs 3.
    [Show full text]
  • RMP Buscopan Part 0 Preliminary Section
    EU RISK MANAGEMENT PLAN FOR HYOSCINE BUTYLBROMIDE PRELIMINARY SECTION Active substance(s) (INN or common name) Hyoscine butylbromide Belladonna alkaloids, semisynthetic, quarternary Pharmaco-therapeutic group (ATC Code) ammonium compounds (ATC code A03BB01) Name of Marketing Authorization Holder or Applicant Boehringer Ingelheim Limited Medicinal product(s) to which this RMP refers Hyoscine butylbromide (BUSCOPAN) (tablet and ampoule) Product(s) concerned (brand name(s)) BUSCOPAN ® (tablet and ampoule) Data lock point (DLP) for current Risk Management Plan 01-JUN-2016 (RMP) Version number of the current RMP Version 2.1_CA Date of final sign-off Property of the Sanofi group - strictly confidential Page 1 QSD-010763 Version 4.0 RISK MANAGEMENT PLAN - Preliminary Section FINAL DLP:01-JUN-2016 Product Code - Hyoscine butylbromide Version 2.1_CA Table 1 - RMP version to be assessed as part of this application RMP Version number Version 2.1_CA Data lock point for this RMP 01-JUN-2016 Date of final sign off Rationale for submitting an updated RMP Not applicable Summary of significant changes in this RMP Safety concerns: The important identified risk “Tachycardia in patients with cardiac risk factors (parenteral formulation)” was added. RMP: Risk Management Plan. Table 2 - Other RMP versions under evaluation RMP Version number Submitted on Submitted within Not applicable - - RMP: Risk Management Plan. Table 3 - Details of the currently approved RMP Version number 2.0 Approved with procedure - Date of approval (opinion date) - RMP: Risk Management
    [Show full text]
  • Muscarinic, Adenosine and Tropomyosin-Related Kinase B Receptor Modulate the Neuromuscular Developmental Synapse Elimination Process
    Muscarinic, adenosine and tropomyosin-related kinase B receptor modulate the neuromuscular developmental synapse elimination process Laura Nadal Magriñà ADVERTIMENT. L'accés als continguts d'aquesta tesi doctoral i la seva utilització ha de respectar els drets de la persona autora. Pot ser utilitzada per a consulta o estudi personal, així com en activitats o materials d'investigació i docència en els termes establerts a l'art. 32 del Text Refós de la Llei de Propietat Intel·lectual (RDL 1/1996). Per altres utilitzacions es requereix l'autorització prèvia i expressa de la persona autora. En qualsevol cas, en la utilització dels seus continguts caldrà indicar de forma clara el nom i cognoms de la persona autora i el títol de la tesi doctoral. No s'autoritza la seva reproducció o altres formes d'explotació efectuades amb finalitats de lucre ni la seva comunicació pública des d'un lloc aliè al servei TDX. Tampoc s'autoritza la presentació del seu contingut en una finestra o marc aliè a TDX (framing). Aquesta reserva de drets afecta tant als continguts de la tesi com als seus resums i índexs. ADVERTENCIA. El acceso a los contenidos de esta tesis doctoral y su utilización debe respetar los derechos de la persona autora. Puede ser utilizada para consulta o estudio personal, así como en actividades o materiales de investigación y docencia en los términos establecidos en el art. 32 del Texto Refundido de la Ley de Propiedad Intelectual (RDL 1/1996). Para otros usos se requiere la autorización previa y expresa de la persona autora. En cualquier caso, en la utilización de sus contenidos se deberá indicar de forma clara el nombre y apellidos de la persona autora y el título de la tesis doctoral.
    [Show full text]
  • Association of Pain with Muscarinic Receptors
    wjpmr, 2018,4(5), 286-295 SJIF Impact Factor: 4.639 WORLD JOURNAL OF PHARMACEUTICAL Research Article Asif et al. AND MEDICAL RESEARCH World Journal of Pharmaceutical and Medical ResearchISSN 2455 -3301 www.wjpmr.com WJPMR ASSOCIATION OF PAIN WITH MUSCARINIC RECEPTORS Dr. Asif Ali*1, Dr. Samia Saba Hamdani2 and Dr. Kiran Shahzadi3 1PMDC # : 85094-P. 2PMDC # : 82129-P. 3PMDC # : 82517-P. *Corresponding Author: Dr. Asif Ali PMDC # : 85094-P. Article Received on 19/03/2018 Article Revised on 09/04/2018 Article Accepted on 30/04/2018 ABSTRACT Pain is an unpleasant experience comes along with any kind of damage and effects daily routine negatively. Although there are various drugs, many of them could not completely succeed in relieving pain due to pain modulation is a complex process involving numerous mediators and receptors. Therefore, it is a rational approach to identifying the components involved in this complex process and develop new agents act on these components. In this respect, the involvement of muscarinic receptors in pain modulation has drawn attention in recent years. The aim of the review is to exhibit the involvement of the muscarinic receptor subtypes that contribute to pain modulation. The search strategy was performed with MeSH terms and free text words, using the bibliographic databases Science Direct and PubMed. The articles have been collected from the experimental animal studies. It is obvious that muscarinic receptors that are located in both peripheral and central areas are extensively involved in the pain process, besides the regional effectiveness of these receptors and their subtypes may vary. Since the muscarinic receptors are various and involve in many physiologic processes, the possibility of adverse effects is a problem in their clinical use.
    [Show full text]
  • Pharmacology and Therapeutics of Bronchodilators
    1521-0081/12/6403-450–504$25.00 PHARMACOLOGICAL REVIEWS Vol. 64, No. 3 Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics 4580/3762238 Pharmacol Rev 64:450–504, 2012 ASSOCIATE EDITOR: DAVID R. SIBLEY Pharmacology and Therapeutics of Bronchodilators Mario Cazzola, Clive P. Page, Luigino Calzetta, and M. Gabriella Matera Department of Internal Medicine, Unit of Respiratory Clinical Pharmacology, University of Rome ‘Tor Vergata,’ Rome, Italy (M.C., L.C.); Department of Pulmonary Rehabilitation, San Raffaele Pisana Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy (M.C., L.C.); Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UK (C.P.P., L.C.); and Department of Experimental Medicine, Unit of Pharmacology, Second University of Naples, Naples, Italy (M.G.M.) Abstract............................................................................... 451 I. Introduction: the physiological rationale for using bronchodilators .......................... 452 II. ␤-Adrenergic receptor agonists .......................................................... 455 A. A history of the development of ␤-adrenergic receptor agonists: from nonselective ␤ Downloaded from adrenergic receptor agonists to 2-adrenergic receptor-selective drugs.................... 455 ␤ B. Short-acting 2-adrenergic receptor agonists........................................... 457 1. Albuterol........................................................................ 457
    [Show full text]